Mizuho Reiterates Buy on Harmony Biosciences, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $54.
October 04, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh has reiterated a 'Buy' rating on Harmony Biosciences and maintained a price target of $54.
The reiteration of a 'Buy' rating by a Mizuho analyst and the maintenance of a $54 price target indicates a positive outlook for Harmony Biosciences. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100